Literature DB >> 2774511

Peripheral pharmacokinetics of apomorphine in humans.

S T Gancher1, W R Woodward, B Boucher, J G Nutt.   

Abstract

Apomorphine, a potent dopamine agonist, has been used in acute and chronic studies of parkinsonism and other neurological disorders. To define its peripheral pharmacokinetics, we administered apomorphine by subcutaneous injection, by subcutaneous infusion, and by intravenous infusion to 15 patients with parkinsonism and measured plasma apomorphine levels by high-performance liquid chromatography with electrochemical detection. The peak drug levels and area under the curve were closely correlated with the dose administered; time to peak was brief and was independent of dose. The variation in absorption was high between subjects but low within individual subjects. In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes. The drug absorption, volume of distribution, plasma clearance, and half-lives were similar for subcutaneous injection, subcutaneous infusion, and intravenous infusion. We conclude that apomorphine is rapidly and completely absorbed from subcutaneous tissue, correlating with the rapid onset of clinical effects, and that the brief duration of clinical action of the drug is explained by its rapid clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2774511     DOI: 10.1002/ana.410260209

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Paradoxical akinetic response to apomorphine in parkinsonism.

Authors:  J R Jenkins; J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

4.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

Authors:  U Sabatini; O Rascol; P Celsis; G Houin; A Rascol; J P Marc-Vergnes; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 5.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

6.  The motor response to sequential apomorphine in parkinsonian fluctuations.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 7.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 9.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

10.  Imaging apomorphine stimulation of brain arachidonic acid signaling via D2-like receptors in unanesthetized rats.

Authors:  Abesh Kumar Bhattacharjee; Lisa Chang; Laura White; Richard P Bazinet; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.